Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
2021 · JAMA Oncology · 336 citations
https://doi.org/10.1001/jamaoncol.2020.7932
J
Jeffrey L. Nordstrom
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
102
Papers
4.9K
Citations
33
h-index
52
i10-index
Jeffrey L. Nordstrom is an academic researcher. The author has contributed to research in topics: Monoclonal and Polyclonal Antibodies Research & CAR-T cell therapy research & RNA Interference and Gene Delivery. The author has an h-index of 33, co-authored 87 publications.
Papers by this author
worksAnti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
2011 · Breast Cancer Research · 244 citations
https://doi.org/10.1186/bcr3069
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
2017 · Annals of Oncology · 224 citations
https://doi.org/10.1093/annonc/mdx002
Cationic Lipids Enhance Cytokine and Cell Influx Levels in the Lung Following Administration of Plasmid: Cationic Lipid Complexes
1998 · The Journal of Immunology · 152 citations
https://doi.org/10.4049/jimmunol.160.9.4580
Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells
2017 · EBioMedicine · 27 citations
https://doi.org/10.1016/j.ebiom.2017.07.019
Margetuximab in HER2-positive metastatic breast cancer
2023 · Future Oncology · 15 citations
https://doi.org/10.2217/fon-2022-1040
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat